These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 18289051)

  • 1. ADAM10 as a target for anti-cancer therapy.
    Moss ML; Stoeck A; Yan W; Dempsey PJ
    Curr Pharm Biotechnol; 2008 Feb; 9(1):2-8. PubMed ID: 18289051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events.
    Moss ML; Bomar M; Liu Q; Sage H; Dempsey P; Lenhart PM; Gillispie PA; Stoeck A; Wildeboer D; Bartsch JW; Palmisano R; Zhou P
    J Biol Chem; 2007 Dec; 282(49):35712-21. PubMed ID: 17895248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer.
    Pruessmeyer J; Ludwig A
    Semin Cell Dev Biol; 2009 Apr; 20(2):164-74. PubMed ID: 18951988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADAM10: a new player in breast cancer progression?
    Mullooly M; McGowan PM; Kennedy SA; Madden SF; Crown J; O' Donovan N; Duffy MJ
    Br J Cancer; 2015 Sep; 113(6):945-51. PubMed ID: 26284334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition.
    Rapti M; Atkinson SJ; Lee MH; Trim A; Moss M; Murphy G
    Biochem J; 2008 Apr; 411(2):433-9. PubMed ID: 18215140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved synthesis of ADAM10 inhibitor GI254023X.
    Hoettecke N; Ludwig A; Foro S; Schmidt B
    Neurodegener Dis; 2010; 7(4):232-8. PubMed ID: 20197648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADAM9 inhibition increases membrane activity of ADAM10 and controls α-secretase processing of amyloid precursor protein.
    Moss ML; Powell G; Miller MA; Edwards L; Qi B; Sang QX; De Strooper B; Tesseur I; Lichtenthaler SF; Taverna M; Zhong JL; Dingwall C; Ferdous T; Schlomann U; Zhou P; Griffith LG; Lauffenburger DA; Petrovich R; Bartsch JW
    J Biol Chem; 2011 Nov; 286(47):40443-51. PubMed ID: 21956108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGF promotes the shedding of soluble E-cadherin in an ADAM10-dependent manner in prostate epithelial cells.
    Grabowska MM; Sandhu B; Day ML
    Cell Signal; 2012 Feb; 24(2):532-538. PubMed ID: 22024284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fendiline inhibits proliferation and invasion of pancreatic cancer cells by interfering with ADAM10 activation and β-catenin signaling.
    Woods N; Trevino J; Coppola D; Chellappan S; Yang S; Padmanabhan J
    Oncotarget; 2015 Nov; 6(34):35931-48. PubMed ID: 26440150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma.
    Kohga K; Takehara T; Tatsumi T; Miyagi T; Ishida H; Ohkawa K; Kanto T; Hiramatsu N; Hayashi N
    Cancer Res; 2009 Oct; 69(20):8050-7. PubMed ID: 19826051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triptolide: An inhibitor of a disintegrin and metalloproteinase 10 (ADAM10) in cancer cells.
    Soundararajan R; Sayat R; Robertson GS; Marignani PA
    Cancer Biol Ther; 2009 Nov; 8(21):2054-62. PubMed ID: 19783906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ADAM10 is upregulated in melanoma metastasis compared with primary melanoma.
    Lee SB; Schramme A; Doberstein K; Dummer R; Abdel-Bakky MS; Keller S; Altevogt P; Oh ST; Reichrath J; Oxmann D; Pfeilschifter J; Mihic-Probst D; Gutwein P
    J Invest Dermatol; 2010 Mar; 130(3):763-73. PubMed ID: 19865098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADAM10 regulates endothelial permeability and T-Cell transmigration by proteolysis of vascular endothelial cadherin.
    Schulz B; Pruessmeyer J; Maretzky T; Ludwig A; Blobel CP; Saftig P; Reiss K
    Circ Res; 2008 May; 102(10):1192-201. PubMed ID: 18420943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells.
    Liu PC; Liu X; Li Y; Covington M; Wynn R; Huber R; Hillman M; Yang G; Ellis D; Marando C; Katiyar K; Bradley J; Abremski K; Stow M; Rupar M; Zhuo J; Li YL; Lin Q; Burns D; Xu M; Zhang C; Qian DQ; He C; Sharief V; Weng L; Agrios C; Shi E; Metcalf B; Newton R; Friedman S; Yao W; Scherle P; Hollis G; Burn TC
    Cancer Biol Ther; 2006 Jun; 5(6):657-64. PubMed ID: 16627989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of retinal axons requires the metalloproteinase ADAM10.
    Chen YY; Hehr CL; Atkinson-Leadbeater K; Hocking JC; McFarlane S
    J Neurosci; 2007 Aug; 27(31):8448-56. PubMed ID: 17670992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reciprocal effects between microRNA-140-5p and ADAM10 suppress migration and invasion of human tongue cancer cells.
    Kai Y; Peng W; Ling W; Jiebing H; Zhuan B
    Biochem Biophys Res Commun; 2014 Jun; 448(3):308-14. PubMed ID: 24530397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The low affinity IgE receptor (CD23) is cleaved by the metalloproteinase ADAM10.
    Lemieux GA; Blumenkron F; Yeung N; Zhou P; Williams J; Grammer AC; Petrovich R; Lipsky PE; Moss ML; Werb Z
    J Biol Chem; 2007 May; 282(20):14836-44. PubMed ID: 17389606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
    Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
    Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting ADAM10 in Cancer and Autoimmunity.
    Smith TM; Tharakan A; Martin RK
    Front Immunol; 2020; 11():499. PubMed ID: 32265938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer.
    Feldinger K; Generali D; Kramer-Marek G; Gijsen M; Ng TB; Wong JH; Strina C; Cappelletti M; Andreis D; Li JL; Bridges E; Turley H; Leek R; Roxanis I; Capala J; Murphy G; Harris AL; Kong A
    Oncotarget; 2014 Aug; 5(16):6633-46. PubMed ID: 24952873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.